As PPARγ agonism is the only available efficacious method to improve peripheral insulin sensitivity, medications of this class remain highly interesting for treatment of T2DM, which underscores the need for new leading compounds that achieve insulin sensitization without severe undesirable adverse effects. This evidence concerns the gene PPARG and type 2 diabetes mellitus.